Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetic patients treated non-surgically (i.e. without amputation or resection of the infected bone) for an osteomyelitis of the foot complicating a neuropathic foot without ischemia of the foot defined as the absence of any pedal pulse. Patients aged of 18 years or more were included if they had type 2 diabetes and osteomyelitis of the foot (i.e.below the ankle).~Exclusion Criteria:~* Patients with gangrene or who require bone resection or amputation when osteomyelitis of the foot was diagnosed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antibiotic therapy (Type: ACTIVE_COMPARATOR): patients are treated with a 6 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h
- 12 week-duration of antibiotic therapy (Type: ACTIVE_COMPARATOR): patients are treated with a 12 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h

Based on this trial design, predict the completion outcome and termination type (if applicable).